AKT1 and prostate carcinoma: In the context of prostate cancer treatment, through multiple synergistic mechanisms, PSP effectively suppressed the activation of the PI3K/AKT and NF-κB signaling pathways, downregulating the phosphorylation of PI3K, AKT, and p65, thereby promoting tumor cell apoptosis and inhibiting growth.